Nordea Investment Management AB Buys 232,690 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Nordea Investment Management AB boosted its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 42.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 777,816 shares of the biopharmaceutical company's stock after acquiring an additional 232,690 shares during the quarter. Nordea Investment Management AB owned 0.59% of Dynavax Technologies worth $10,034,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in DVAX. Renaissance Technologies LLC increased its holdings in shares of Dynavax Technologies by 2.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company's stock worth $27,830,000 after acquiring an additional 53,600 shares during the last quarter. Great Point Partners LLC increased its holdings in shares of Dynavax Technologies by 87.7% in the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company's stock valued at $26,660,000 after purchasing an additional 1,109,080 shares during the last quarter. Millennium Management LLC bought a new position in shares of Dynavax Technologies in the second quarter valued at about $17,615,000. Mizuho Markets Americas LLC lifted its stake in shares of Dynavax Technologies by 17.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company's stock worth $15,369,000 after buying an additional 204,475 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in shares of Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company's stock worth $11,848,000 after buying an additional 82,449 shares during the period. Institutional investors and hedge funds own 96.96% of the company's stock.

Dynavax Technologies Stock Performance

NASDAQ DVAX traded up $0.01 on Friday, reaching $12.63. The stock had a trading volume of 1,708,042 shares, compared to its average volume of 2,266,840. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company has a market cap of $1.66 billion, a P/E ratio of 97.16 and a beta of 1.34. The firm has a fifty day moving average of $12.74 and a two-hundred day moving average of $11.63. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $14.41.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and issued a $29.00 price target on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.